Live Chat ×
Skip to main content

Ask the Expert Webinar: Pharmacokinetics, Safety and Efficacy of Cannabidiol in Treating Epilepsy

Activity provided by the American Epilepsy Society.
Recording date: April 23, 2019
Activity Launch date: April 29, 2019
Expiration date: April 29, 2022 




Overview

The tremendous interest in the lay community to use cannabidiol to treat epilepsy has outpaced our knowledge. This  recorded webinar seeks to provide a basic level of information regarding our current knowledge of cannabidiol, its mechanism of action, pharmacology as well as its safety and efficacy for children and adults with epilepsy.

References:
Cannabinoid therapy in epilepsy. (https://www.ncbi.nlm.nih.gov/pubmed/30676535) Billakota S, Devinsky O, Marsh E. Curr Opin Neurol. 2019 Jan 22.

Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M,Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM; GWPCARE3 Study Group.N Engl J Med. 2018 May 17;378(20):1888-1897.

Target Audience

Epileptologists, neurologists, pharmacologists, advanced practice providers, nurses and epilepsy specialist allied health professionals

Learning Objectives

Following participation in this activity, the learner should be able to:

  • Describe leading candidate mechanism(s) of action for cannabidiol in the treatment of epilepsy.
  • Discuss potential or known drug interactions of cannabidiol with other approved anti-seizure medications
  • Define the populations in which cannabidiol has proven efficacy.

Faculty

Moderators:
Ignacio Valencia, MD,  Drexel University College of Medicine, Philadelphia, PA

Jeannine Conway, PharmD, BCPS, University of Minnesota College of Pharmacy, Minneapolis, MN

Presenter:
Orrin Devinsky, MD, NYU Lagone Comprehensive Epilepsy Center, New York, NY

Disclosure Policy
It is the policy of the American Epilepsy Society to ensure balance, independence, objectivity and scientific rigor. All individuals involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. Conflicts of interest will be resolved by AES prior to an educational activity being delivered to learners.

Faculty, Planning Committee, Reviewers’ Disclosures of Financial Relationships

In accordance with the ACCME Standards for Commercial Support, the AES requires that any person who is in a position to control content of a CME activity must disclose all relevant financial relationships that they have with a commercial interest. The following individuals contributed to this activity’s content.

Faculty & Planners

Webinar Workgroup Members

David Ficker, MD, Chair, Webinar Workgroup, Cincinnati Medical Center, Cincinnati, OH
Dr. Ficker has disclosed the following relevant relationships:
  • Lundbeck: Honoraria
  • Best Doctors: Consulting fee
Ignacio Valencia, MD, Moderator, Drexel University College of Medicine, Philadelphia, PA
Dr. Valencia has indicated that he has no financial relationships with commercial interests to disclose

Madison Berl, PhD, Children’s National Medical Center, Washington, DC
Dr. Berl has indicated that she has no financial relationships with commercial interests to disclose

Nurse Planner
Madona Plueger, ACNS, CNRN, MSN, Barrow Neurological Institute, Phoenix, AZ
Dr. Plueger has indicated that she has no financial relationships with commercial interests to disclose

Pharmacy Planner
Jeannine Conway, PharmD, BCPS, Moderator, University of Minnesota College of Pharmacy, Minneapolis, MN
Dr. Conway has disclosed the following relevant relationships:
  • UCB Pharma Inc.: Epilepsy Pharmacist Working Group; consulting fee
  • Greenwich Biosciences: Cannabinoid Education Working Group; honoraria 

Orrin Devinsky, MD, NYU Lagone Comprehensive Epilepsy Center, New York, NY
Dr. Devinsky has disclosed the following relevant relationships:
  • GW: Principal Investigator for GW Epidiolex Open-Label and Randomized Controlled Trials; Consultant
  • Tilray, Papa & Barkley: Medical Advisory Board, Chair; equity interest
  • Receptor Life Sciences: Chief Medical Officer; equity interest
CME Reviewer
Jay Salpekar, MD, Kennedy Krieger Institute, Baltimore, MD
Dr. Salpekar has disclosed the following relevant relationships:
  • Lundbeck: Investigator initiated study- research funding to institution only; contracted research

American Epilepsy Society Staff Planner
Amy Kephart, MPH, American Epilepsy Society, Chicago, IL
Ms. Kephart has indicated she has no financial relationships with commercial interests to disclose.

Resolution of Conflicts of Interest

It is the policy of the American Epilepsy Society to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. In accordance with the ACCME Standards for Commercial Support of CME, the AES implemented the mechanisms of prospective peer review of this CME activity, to identify and resolve any conflicts. Additionally, the content of this activity is based on the best available evidence.

Accreditation
The American Epilepsy Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
For more information regarding contact hours, please call American Epilepsy Society 312.883.3800.

Credit Designation
The American Epilepsy Society designates this live activity for a maximum of .5 AMA PRA Category 1 Credit™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.




In support of improving patient care, University of Minnesota, Interprofessional Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

The Universal Activity Number is JA0000810-9999-19-036-L01-P. This knowledge-based online activity has been approved for .5 contact hours.

International Credits: The American Medical Association has determined that non-US. licensed physicians who participate in this CME activity are eligible for AMA PRA Category 1 Credits™.

Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.5 hours of Category 1 credit for completing this program.

CME and CE Certificates
To receive credit for your participation in this activity, please complete the evaluation survey provided at the conclusion of the activity.

Unapproved Use Disclosure

The American Epilepsy Society requires CME authors to disclose to learners when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Information about pharmaceutical agents/devices that is outside of U.S. Food and Drug Administration approved labeling may be contained in this activity.

Disclaimer

This CME activity is for educational purposes only and does not constitute the opinion or endorsement of, or promotion by, the American Epilepsy Society. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label, investigational and/or experimental uses.